Browse the evidence

The incidence of completed or attempted suicide and occurrences of suicidal ideation or self-harm is very low in individuals receiving GLP-1 receptor agonists (0.047 per 100 person-years) compared to placebo (0.042 per 100 person-years), with no statistically significant difference.

Practitioners can be reassured that GLP-1 RAs do not appear to increase the risk of suicidality in their patients.

There is unlikely to be an increase in the very low incidence of suicide-related adverse events among individuals receiving GLP-1 receptor agonists within the context of randomized controlled trials.

Healthcare providers can continue to prescribe GLP-1 RAs without heightened concern for suicidality in clinical settings.

Expanded Medicare coverage for GLP-1 receptor agonists (GLP-1RAs) for obesity treatment is projected to increase total Medicare drug costs by $65.9 billion over 10 years.

Practitioners should be aware of the significant projected costs associated with GLP-1RA coverage under Medicare.

The net increased spending due to expanded Medicare coverage for GLP-1RAs is projected to be $47.7 billion over 10 years.

Practitioners should be aware of the substantial net spending implications of GLP-1RA coverage.

No association was found with other disorders of the optic nerve or visual pathways.

Other optic nerve or visual pathway disorders are not linked to semaglutide or tirzepatide use.

There is a need to end disparities in cardiovascular morbidity and mortality related to race, sex, and income inequality.

Healthcare systems should implement strategies to reduce these disparities.

In monozygotic twin pairs, higher BMI was not associated with an increased risk of myocardial infarction (MI) or death.

Practitioners may consider that higher BMI in twins does not necessarily indicate a higher risk for MI or death.

Semaglutide did not increase or reduce the risk of eye disorders (OR, 1.01; 95% CI, 0.91-1.12) or diabetic retinopathy (OR, 1.04; 95% CI, 0.92-1.17).

Semaglutide can be considered safe regarding eye disorders and diabetic retinopathy.

The SMM/ICW ratio did not change in either the creatine or placebo group.

Creatine does not affect the ratio of intracellular water to muscle mass in resistance-trained individuals.

Food and beverage industries' participation in health scientific events can lead to conflicts of interest.

Health professionals should be cautious of partnerships with food and beverage industries at scientific events.

Corporate sponsors significantly influence the scientific programs of health events.

Event organizers should be aware of the potential for corporate influence on scientific content.

There was no significant association between carbohydrate intake and mortality (p trend =0.69).

Carbohydrate intake may not be a significant factor in overall mortality for this demographic.

Regainers in the MedWeight study were older than maintainers.

Understanding age differences may help tailor weight loss strategies for different age groups.

Dietary intake of total protein was not significantly associated with the risk of total coronary heart disease (CHD) and hypertension (HTN).

Total protein intake does not appear to increase the risk of CHD or HTN.

Dietary intake and biomarkers of total fat and saturated, monounsaturated, and polyunsaturated fatty acids were not associated with the risk of coronary events.

Practitioners should note that total fat and specific fatty acids do not appear to influence coronary event risk.

Challenges to scaling FIM programs include incorporating them into health care business models and educating the health care workforce.

Stakeholders should focus on developing business models and training programs to effectively scale FIM interventions.

The rate of hospitalisations for SAP was 25.3% during the reference period before surgery.

Understanding pre-surgery hospitalisation rates can help gauge the impact of bariatric surgery.

The rate of hospitalisations for SAP remained stable in the 12-month presurgery period.

The stability of hospitalisation rates before surgery suggests a consistent health status in this population.

No recent or older studies show any effect of nutritional interventions on muscle protein gain.

Nutritional interventions may not be effective for muscle protein gain in ICU patients.

Existing pharmacologic formulations for obesity have not provided optimal clinical efficacy and have had many concerning adverse effects.

Practitioners should be aware of the limitations and adverse effects of current obesity pharmacotherapies.

Statistical guidance and study designs are necessary to measure treatment response heterogeneity in nutrition and obesity research.

Researchers should adopt appropriate statistical methods and study designs to accurately assess treatment responses.

Semaglutide treatment is not associated with higher rates of short-term adverse events after cervical spine decompression and fusion in patients with Type 2 Diabetes Mellitus.

Practitioners can consider that semaglutide treatment does not increase short-term surgical risks in this patient population.

There are no statistically significant differences in the composite measure of postoperative surgical complications between semaglutide-treated patients and controls.

The findings suggest that semaglutide does not negatively impact surgical outcomes in this context.

The 30-day and 90-day readmission rates were similar between semaglutide-treated patients and controls.

This indicates that semaglutide does not increase the likelihood of readmission after surgery.